[Tumor markers of prostate cancer--evaluation of serum PAP and PA].
The clinical usefulness of PAP and PA as a tumor marker for the prostate cancer were discussed. The materials for this study were 1385 cases which contained 158 cases with prostatic carcinoma. The positive rate of serum PAP and PA were 77.7% and 94.1% in untreated prostatic carcinoma and 15.1% and 70.0% in benign prostatic hypertrophy using 3.0 ng/ml as an upper limit of normal controls of serum PAP and PA. The cut off level in serum PA should be discussed more. PA was not superior to PAP as a tumor marker in the series, but our results have suggested the simultaneous assay of serum PAP and PA is valuable in detection and following-up of prostate cancer.
Miki
M
M
D000135:Acid Phosphatase / Q000032:analysis*; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000201:enzymology*; D017430:Prostate-Specific Antigen; D011470:Prostatic Hyperplasia / Q000201:enzymology / Q000276:immunology; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000276:immunology*; D011472:Prostatitis / Q000201:enzymology / Q000276:immunology
D000951:Antigens, Neoplasm; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen